Defence Therapeutics Inc. (CSE:DTC)
Canada · Delayed Price · Currency is CAD 0.5200
+0.0100 (1.96%)
Aug 28, 2026, 3:06 PM EST
Defence Therapeutics Balance Sheet
Financials in millions CAD. Fiscal year is July - June.
Millions CAD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 2.95 | 1.23 | 0.06 | 2.79 | 0.51 | 5.45 |
Cash & Short-Term Investments | 2.95 | 1.23 | 0.06 | 2.79 | 0.51 | 5.45 |
Cash Growth | 41.99% | 2079.47% | -97.97% | 451.20% | -90.71% | 192.24% |
Other Receivables | 0.32 | 0.2 | 0.1 | 0.15 | 0.03 | 0.07 |
Receivables | 0.32 | 0.2 | 0.1 | 0.15 | 0.03 | 0.07 |
Prepaid Expenses | 0.01 | 0.03 | 0.06 | 0.49 | 0.14 | 0.04 |
Total Current Assets | 3.28 | 1.46 | 0.21 | 3.43 | 0.67 | 5.56 |
Property, Plant & Equipment | 0.17 | 0.19 | 0.26 | 0.06 | - | - |
Other Intangible Assets | - | - | - | 0.04 | 0.05 | 0.05 |
Total Assets | 9.45 | 1.65 | 0.48 | 3.53 | 0.72 | 5.61 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accounts Payable | 0.97 | 1.33 | 2.09 | 0.19 | 0.98 | 0.11 |
Short-Term Debt | - | - | 0.05 | - | - | - |
Current Portion of Long-Term Debt | - | 1.49 | 1.66 | - | - | - |
Current Portion of Leases | - | 0.02 | 0.03 | - | - | - |
Other Current Liabilities | - | 0.07 | 0.22 | 0.03 | 0.13 | 0.01 |
Total Current Liabilities | 0.97 | 2.91 | 4.05 | 0.22 | 1.11 | 0.12 |
Long-Term Debt | 1.56 | - | - | 1.75 | - | - |
Long-Term Leases | - | - | 0.01 | - | - | - |
Total Liabilities | 4.03 | 2.91 | 4.06 | 1.97 | 1.11 | 0.12 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 32.87 | 24.19 | 19.24 | 16.95 | 9.33 | 7.97 |
Retained Earnings | -34.27 | -29.31 | -29.81 | -16.91 | -10.52 | -3.53 |
Comprehensive Income & Other | 6.81 | 3.86 | 6.98 | 1.52 | 0.79 | 1.05 |
Shareholders' Equity | 5.41 | -1.26 | -3.58 | 1.57 | -0.39 | 5.49 |
Total Liabilities & Equity | 9.45 | 1.65 | 0.48 | 3.53 | 0.72 | 5.61 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Total Debt | 1.56 | 1.5 | 1.75 | 1.75 | - | - |
Net Cash (Debt) | 1.39 | -0.27 | -1.69 | 1.05 | 0.51 | 5.45 |
Net Cash Growth | 102.11% | - | - | 106.61% | -90.71% | 192.24% |
Net Cash Per Share | 0.02 | -0.01 | -0.04 | 0.03 | 0.01 | 0.21 |
Filing Date Shares Outstanding | 75.79 | 54.73 | 45.54 | 44.27 | 37.68 | 35.96 |
Total Common Shares Outstanding | 75.59 | 54.73 | 45.54 | 43.78 | 36.63 | 35.22 |
Working Capital | 2.3 | -1.44 | -3.84 | 3.21 | -0.43 | 5.44 |
Book Value Per Share | 0.07 | -0.02 | -0.08 | 0.04 | -0.01 | 0.16 |
Tangible Book Value | 5.41 | -1.26 | -3.58 | 1.53 | -0.43 | 5.44 |
Tangible Book Value Per Share | 0.07 | -0.02 | -0.08 | 0.03 | -0.01 | 0.15 |
Machinery | 0.28 | 0.27 | 0.27 | 0.07 | - | - |